(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 13.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Foghorn Therapeutics's revenue in 2026 is $30,909,000.On average, 12 Wall Street analysts forecast FHTX's revenue for 2026 to be $2,042,123,597, with the lowest FHTX revenue forecast at $0, and the highest FHTX revenue forecast at $3,562,731,207. On average, 12 Wall Street analysts forecast FHTX's revenue for 2027 to be $2,349,592,955, with the lowest FHTX revenue forecast at $1,108,405,264, and the highest FHTX revenue forecast at $3,633,985,831.
In 2028, FHTX is forecast to generate $2,566,467,149 in revenue, with the lowest revenue forecast at $1,108,405,264 and the highest revenue forecast at $4,871,610,791.